309 related articles for article (PubMed ID: 17984312)
1. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
Pietra D; Li S; Brisci A; Passamonti F; Rumi E; Theocharides A; Ferrari M; Gisslinger H; Kralovics R; Cremonesi L; Skoda R; Cazzola M
Blood; 2008 Feb; 111(3):1686-9. PubMed ID: 17984312
[TBL] [Abstract][Full Text] [Related]
2. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
[TBL] [Abstract][Full Text] [Related]
3. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
4. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
[TBL] [Abstract][Full Text] [Related]
5. Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.
Leszczynska A; Grzenkowicz-Wydra J; Chmielewska-Gorycka L; Bieniaszewska M; Hellmann A
Acta Haematol; 2016; 136(2):123-8. PubMed ID: 27410038
[TBL] [Abstract][Full Text] [Related]
6. [JAK2 exon 12 mutations in patients with Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms].
Wang JY; Ai XF; Xu JQ; Li QH; Xu ZF; Qin TJ; Zang Y; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Sep; 33(9):705-9. PubMed ID: 23336221
[TBL] [Abstract][Full Text] [Related]
7. Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis.
Ohyashiki JH; Hisatomi H; Shimizu S; Sugaya M; Ohyashiki K
Jpn J Clin Oncol; 2009 Aug; 39(8):509-13. PubMed ID: 19491085
[TBL] [Abstract][Full Text] [Related]
8. High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance.
Park CH; Lee KO; Jang JH; Jung CW; Kim JW; Kim SH; Kim HJ
J Clin Pathol; 2016 Aug; 69(8):737-41. PubMed ID: 27198504
[TBL] [Abstract][Full Text] [Related]
9. High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera.
Yeh YM; Chen YL; Cheng HY; Su WC; Chow NH; Chen TY; Ho CL
Am J Clin Pathol; 2010 Aug; 134(2):266-70. PubMed ID: 20660330
[TBL] [Abstract][Full Text] [Related]
10. Detection Mutations of JAK2 exon 12 in Patients with JAK2 (V617F)-negative Myeloproliferative Disorders.
Makani SZ; Parsamanesh N; Mirzaahmadi S; Hashemi M; Shaveisi-Zadeh F; Mansouri N; Ghazi M; Movafagh A
Gulf J Oncolog; 2017 May; 1(24):15-19. PubMed ID: 28797996
[TBL] [Abstract][Full Text] [Related]
11. [JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].
Kim JT; Cho YG; Choi SI; Lee YJ; Kim HR; Jang SJ; Moon DS; Park YJ; Park G
Korean J Lab Med; 2010 Dec; 30(6):567-74. PubMed ID: 21157140
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of JAK2 mutations in myeloproliferative disorders.
Knoops L; Hermans C; Ferrant A; Constantinescu SN
Acta Clin Belg; 2008; 63(2):93-8. PubMed ID: 18575049
[TBL] [Abstract][Full Text] [Related]
13. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
14. Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.
Alghasham N; Alnouri Y; Abalkhail H; Khalil S
Int J Lab Hematol; 2016 Feb; 38(1):34-41. PubMed ID: 26361084
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of chronic myeloproliferative neoplasias in México.
Ruiz-Argüelles GJ; Garcés-Eisele J; Ortiz-López R; Rivas-Llamas R; Gómez-Almaguer D; Ruiz-Delgado GJ
Hematology; 2009 Oct; 14(5):261-5. PubMed ID: 19843380
[TBL] [Abstract][Full Text] [Related]
16. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
17. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
18. JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.
Ma W; Kantarjian H; Zhang X; Wang X; Zhang Z; Yeh CH; O'Brien S; Giles F; Bruey JM; Albitar M
PLoS One; 2010 Aug; 5(8):e12165. PubMed ID: 20730051
[TBL] [Abstract][Full Text] [Related]
19. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
20. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
